Sera Prognostics, a company specializing in women's reproductive health, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy solicitation process. This filing, known as a DEFA14A, indicates that Sera Prognostics is providing further materials to its shareholders in relation to the proxy statements already issued under Section 14(a) of the Securities Exchange Act of 1934. The company has confirmed that no filing fee is required for this submission. The materials are intended to supplement information previously provided to shareholders and may be related to upcoming shareholder meetings or voting procedures.

Sera Prognostics, a company specializing in women's reproductive health, has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy solicitation process. This filing, known as a DEFA14A, indicates that Sera Prognostics is providing further materials to its shareholders in relation to the proxy statements already issued under Section 14(a) of the Securities Exchange Act of 1934. The company has confirmed that no filing fee is required for this submission. The materials are intended to supplement information previously provided to shareholders and may be related to upcoming shareholder meetings or voting procedures.